Vaccine is produced in Vero cell technology.The company claims the vaccine is the first cell culture-based, nonadjuvanted pandemic flu vaccine to get EU clearance.
The Broad Institute of Harvard and MIT has adopted Genedata’s Screener® for small molecule screening. The Screener will be used in the institute’s contribution...
JV with WalVax will allow local manufacture of GSK’s measles, mumps, and rubella (MMR) Priorix™. GSK also has Chinese JV for seasonal, prepandemic, and pandemic influenza vaccines.
Joint effort will exploit Theraclone’s I-START technology platform.The technology is based on the interrogation of memory B-cell archives.
Rapid multiplexed assays will be designed on a Luminex® xMap® platform. Targets include Bacillus anthracis (anthrax), Yersinia pestis (plague), and Francisella tularensis (tularemia).
Small molecules are being developed for cardiovascular and pulmonary indications. Arginetix closed a $10.75 million Series A financing. The company is developing small molecule inhibitors...
Drugs for Neglected Diseases initiative will carry out clinical trials of ravuconazole prodrug.
The deal includes flu-mAB, a universal product against all influenza A strains including seasonal and pandemic H1N1 and the avian H5N1 strain.
Antifungal SUB-Itraconazole is a super-bioavailable formulation of the synthetic broad-spectrum itraconazole. Johnson & Johnson’s branded version is called Sporanox.